In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of He... (a 42 percent reduction in heartattack wi...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> MEDICINE >> NEWS

In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack

Date:11/4/2007

a 42 percent reduction in heart attack with subsequent death from cardiovascular causes (p=0.02).

While the overall incidence of non-CABG (coronary artery bypass grafting) bleeding in TRITON was low in both the prasugrel and clopidogrel treatment groups, prasugrel-treated patients experienced a statistically significant increase in non-CABG (coronary artery bypass grafting) major bleeding compared to clopidogrel-treated patients (2.4 vs. 1.8 percent, or 146 vs. 111 patients, p=0.03), including higher rates of life-threatening bleeding (1.4 vs. 0.9 percent, or 85 vs. 56 patients, p=0.01). Though infrequent, fatal bleeding was statistically more frequent among prasugrel-treated than clopidogrel-treated patients (0.4 percent vs. 0.1 percent, or 21 vs. five patients, p=0.002). However, death from cardiovascular causes occurred less frequently among prasugrel-treated patients than clopidogrel-treated patients (2.1 percent vs. 2.4 percent, or 133 vs. 150 patients, p=0.31), as did all-cause death (3.0 percent vs. 3.2 percent, or 188 vs. 197 patients, p=0.64).

The study identified three distinct patient subpopulations with a higher risk of major bleeding in both treatment arms - patients who were 75 years of age or older, weighed less than 60 kg (132 lbs.), or had a prior history of transient ischemic attack (TIA) or stroke. Researchers are evaluating pharmacokinetic data from several prasugrel studies, including TRITON, to determine whether a lower dose of prasugrel might be appropriate for some patients. Among patients without any of these risk factors (80 percent of the 13,608-patient TRITON study), there was no significant difference in major bleeding between prasugrel- and clopidogrel-treated patients (2 percent vs. 1.5 percent, p=0.17).

Based on an analysis using the combined endpoint of all-cause death, heart attack, stroke and major bleeding, the net clinical benefit for prasugrel compared with clopidogrel was a significant 13 percent reduction in
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7
Related medicine news :

1. South Africa Wins landmark case against pharmaceutical giants
2. Kolkata: Landmark Health City on the Cards
3. Heart Center at Sinai Conducts Landmark Study on Aspirin Resistance
4. Scientists Map Key Landmarks in Human Genome
5. Landmark Study Prompts Rethink of Genetic Code
6. FDA approves Phase 0 trial which tests experimental drugs on humans
7. SARS-Free Taiwan to Mark End Phase of Global Fight
8. S. Africa AIDS in death phase
9. Spray on contraceptive clears Phase I trial
10. Phase 3 trials of two multi-kinase inhibitors against cancer
11. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine

Post Your Comments:

Breaking Medicine News(10 mins):Health News:Effort to Regenerate Injured Spinal Cords Turns to a New Model 2 Health News:Effort to Regenerate Injured Spinal Cords Turns to a New Model 3 Health News:Effort to Regenerate Injured Spinal Cords Turns to a New Model 4 Health News:Alcohol Countermeasure Systems Penetrates New Markets Through Acquisition of Seres Ethylometre of France 2 Health News:New Hope for Brain, Spinal Cord Injuries 2 Health News:Drug Information Association (DIA) Announces New Clinical Safety and Pharmacovigilance Certificate Program 2 Health News:Drug Information Association (DIA) Announces New Clinical Safety and Pharmacovigilance Certificate Program 3

[0] Stem Cells Turned Into AIDS Killers in Lab Tests [0] Effort to Regenerate Injured Spinal Cords Turns to a New Model [0] Alcohol Countermeasure Systems Penetrates New Markets Through Acquisition of Seres Ethylometre of France [0] New Hope for Brain, Spinal Cord Injuries [0] Drug Information Association (DIA) Announces New Clinical Safety and Pharmacovigilance Certificate Program

Is There Really Such a Thing as Hope in a Jar?CDC Reports Drop in Adult Smoking, But Death Toll and Health Costs Are Still Growing; Congress, States Should Implement Proven Solutions Elizabeth Edwards Reschedules Metro Detroit Appearance HIV Vaccine Failure Still Brings Insights Misonix Reports First Quarter Fiscal Year 2009 Financial Results Relationship between prostate information and lower urinary-tract symptoms evident

Breaking Medicine Technology:Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 2 Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 3 Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 4 Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 5 Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 6 Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 7 GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 2 GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 3 GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 4 GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 5 GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 6 Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 2 Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 3 Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 4 IMAGINE Software Unveils Advanced IMAGINEradiology 28TM 29 Features 47841 1 IMAGINE Software Unveils Advanced IMAGINEradiology 28TM 29 Features 47841 2 Americas Future Now Straw Poll 3A Progressives See Health Care Reform With Public Option As Top Priority 47838 1 Americas Future Now Straw Poll 3A Progressives See Health Care Reform With Public Option As Top Priority 47838 2 Medical Insurance Automotive and Safety Groups Call on Congress to Make This the 22Last Deadly Summer for Teens 22 by Swiftly Passing Federal Teen 47835 1 Medical Insurance Automotive and Safety Groups Call on Congress to Make This the 22Last Deadly Summer for Teens 22 by Swiftly Passing Federal Teen 47835 2 Medical Insurance Automotive and Safety Groups Call on Congress to Make This the 22Last Deadly Summer for Teens 22 by Swiftly Passing Federal Teen 47835 3

[0] Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies [0] GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer [0] Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders

Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica Senesco's Preclinical Pancreatic Islet Data to be Presented at Upcoming Conferences

Medicine Products:

Lupus Anticoagulant Panel with Reflex to 1:1 Mixes & Confirmations Luminal Lp(a)Low Density Lipoprotein, Direct

In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of He...(a 42 percent reduction in heartattack wi...),Health